Lipid-coated condensed-phase microparticle composition

• US 5,753,261 A
• Filed: 05/17/1995
• Issued: 05/19/1998
• Est. Priority Date: 02/12/1993
• Status: Expired due to Fees

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Access Pharmaceuticals Inc.
• Inventors: Fernandez, Julio M., Knudson, Mark B.
• Primary Examiner(s): Kishore, Gollamudi S.
• Application Number:
  US08/443,402
• Time in Patent Office: 1,098 Days
• Field of Search: 424/450, 424/489, 424/484, 424/485, 424/486, 424/487, 424/488, 424/499, 424/500, 424/501, 424/1.21, 424/9.4, 428/402.2
• US Class Current: 424/450
• CPC Class Codes: A61K 8/14 Liposomes; Vesicles
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61Q 7/00 Preparations for affecting hair growth
• CPC Class Codes: G01N 33/586 Liposomes, microcapsules or cells

Abstract

A microparticle composition for use in compound delivery, when the composition is exposed to a selected target stimulus related to pH, temperature, radiation, or the presence of a selected ligand or ion-channel activator, is disclosed. The composition includes a condensed-phase particle matrix containing the compound to be delivered in entrapped form, and a stimulus-responsive lipid bilayer membrane formed around the matrix. Localized perturbation of the lipid membrane, and influx of monovalent counterions into the polymer matrix, in response to the selected target stimulus, causes matrix swelling and compound release from the particles.

Claims

1. A composition for release of a compound upon exposure to a target stimulus selected from the group consisting of pH, temperature, radiation, a ligand and an ion-channel activator, comprising

encapsulated microparticles having an average size between 0.05 and 5 microns, each encapsulated microparticle being composed of

(i) an external lipid bilayer membrane effective to allow influx of external ions into the particle interior when exposed to said target stimulus,

(ii) encapsulated within the lipid membrane, a condensed-phase microparticle which is composed of a matrix of crosslinked polyionic polymer filaments, and which is capable of decondensing to an expanded state when multivalent counterions also present within the matrix are replaced by monovalent counterions, and

(iii) the compound to be released entrapped in the microparticle matrix, with said matrix in its condensed phase,

whereby localized perturbation of the lipid membrane, and influx of monovalent counterions into the microparticle matrix, in response to said target stimulus, causes swelling and compound release from said microparticles.

2. The composition of claim 1, wherein the microparticles have an average size 0.05 and 0.5 microns, the compound is a therapeutic compound, and the lipid membrane is effective to allow influx of external counterions into the microparticle matrix when exposed to said target stimulus in vivo.

3. The composition of claim 2, wherein the polymer filaments forming the microparticle matrix are sulfated, sulfonated, carboxylated, or polyphosphated polyanionic polymers, and the multivalent counterion is a multivalent cation.

4. The composition of claim 3, wherein the filaments forming the microparticle matrix are comb-polymer glycoprotein filaments.

5. The composition of claim 2, wherein the halflife of matrix swelling, following localized perturbation of the membrane, is less than about 1 sec.

6. The composition of claim 2, wherein said microparticle matrix contains less than about 30 volume percent of an aqueous medium and said therapeutic compound is at a concentration which exceeds its solubility in the aqueous medium.

7. The composition of claim 2, which further comprises anti-ligand molecules attached to the eternal lipid-membrane surfaces of said encapsulated microparticles, for binding specifically to antigen or antibody molecules present at such in vivo site.

8. The composition of claim 2, wherein said target stimulus is heat and said lipid bilayer membranes are formed of lipids having a phase transition temperature above normal body temperature.

9. The composition of claim 2, for delivering said compound to a target region containing an activator for an ion channel protein, wherein said lipid membrane further comprises an ion-selective channel.

10. The composition of claim 9, wherein said ion channel is a calcium-activated ion channel.

11. The composition of claim 10, wherein the ion channel is a calcium-activated potassium channel.

12. The composition of claim 9, wherein said ion channel is a ligand-gated ion channel.

13. The composition of claim 12, wherein the channel is a glutamate receptor.

14. The composition of claim 12, wherein the channel is a nicotinic acetylcholine receptor.

15. The composition of claim 1, wherein the encapsulated microparticles'"'"' lipid membranes include a plasmalogen lipid having a vinyl ether functional group capable of cleavage in response to acidic conditions or a reactive oxygen species.

16. The composition of claim 15, wherein the encapsulated microparticle further comprises a lysogenic substance that, in response to photoillumination, produces a reactive oxygen species effective to cleave the vinyl ether functional group of the plasmalogen.

17. The composition of claim 15, wherein the microparticle matrix further comprises a lysogenic substance that, in response to photoillumination, produces acid effective to cleave the vinyl ether functional group of the plasmalogen.

18. The composition of claim 15, wherein the plasmalogen is 1-alk-1'"'"'-enyl-2-palmitoyl-sn-glycero-3 phosphocholine.

19. The composition of claim 1, wherein said lipid bilayer membranes include a light-sensitive lipid capable of changing conformation in response to exposure to light at a pre-determined wavelength.

20. The composition of claim 19, wherein the light-sensitive lipid is a retinoyl-sn-glycero-3-phosphocholine.